April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The company has received a commitment of up to $12.5 million in a multi-draw DIP financing facility to provide funding during the proceeding.

NEW YORK — Exagen, a developer of autoimmune testing technologies, said on Thursday it expects to raise around $17.6 million through a public offering of its common stock.

The firm has been engaging with payors and insurance plan administrators following the release of results from its study on the use of the firm's PreTRM Test.